Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase π, heat shock protein 27, and lung resistance- related protein) in osteosarcoma: Relationship with poor prognosis

Cancer

Volumn 79, Issue 12, 1997, Pages 2336-2344

  Uozaki, Hiroshi ^a   Horiuchi, Hajime ^a   Ishida, Tsuyoshi ^a   Iijima, Takuo ^a   Imamura, Tetsuo ^b   Machinami, Rikuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Drug resistance; Glutathione S transferase ; Heat shock protein 27; Immunohistochemistry; Lung resistance related protein; Metallothionein; Osteosarcoma; Prognosis

Indexed keywords

GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN; METALLOTHIONEIN;

ADULT; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLUTATHIONE TRANSFERASE; HEAT-SHOCK PROTEINS; HUMANS; MALE; METALLOTHIONEIN; NEOPLASM PROTEINS; OSTEOSARCOMA; PROGNOSIS; SURVIVAL ANALYSIS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0030902367     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J     Document Type: Article

References (47)

1. Gill M, McCarthy M, Murrells T, Silcocks P. Chemotherapy for the primary treatment of osteosarcoma: population effectiveness over 20 years. Lancet 1988;8587:689-92.
2. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop 1991;270:8-14.
3. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 1976;455:152-62.
4. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
5. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993;53:1475-9.
6. Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1987;19:149-54.
7. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992;89:3070-4.
8. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J, et al. Glutathione-S-transferase π as a determinant of drug resistance in transfectant cell lines. J Biol Chem 1990;265:4296-301.
9. Huot J, Roy G, Lambert H, Chretien P, Landry J. Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. Cancer Res 1991;51:5245-52.
10. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, et al. Characterization of mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 1987;84:5565-9.
11. Volm M, Mattern J. Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits. Cardnogenesis 1992;13:1947-50.
12. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980;153:106-20.
13. Dahlin DC, Unni KK. Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol 1977;1:61-72.
14. Bier B, Douglas-Jones A, Totsch M, Dockhorn-Dworniczak B, Bocker W, Jasani B, et al. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat 1994;30:213-21.
15. Ciocca DR, Adams DJ, Edwards DP, Bjercke RJ, McGuire WL. Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells. Cancer Res 1983;43:1204-10.
16. Kantor RR, Giardina SL, Bartolazai A, Townsend AJ, Myers CE, Cowan KH, et al. Monoclonal antibodies to glutathione S-transferase π - immunohistochemical analysis of human tissues and cancers. Int J Cancer 1991;47:193-201.
17. Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230-7.
18. Fisher RA, Yate F. Statistical tables for biological, agricultural and medical research. Edinburgh: Oliver and Boyd. 1970.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Hayashi K. Histopathological study of the effect of preoperative chemotherapy on osteosarcoma. J Jpn Orthop Assoc 1994;68:151-61.
21. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995;75:1084-93.
22. Wang AL, Tew KD. Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards. Cancer Treat Res 1985;69:677-82.
23. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986;261:15544-9.
24. Fresno M, Wu W, Rodriguez JM, Nadji M. Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1993;423:215-9.
25. Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams R. Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 1994;152:2272-5.
26. Ofner D, Maier H, Riedmann B, Bammer T, Rumer A, Winde G, et al. Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival. Virchows Arch 1994;425:491-7.
27. Campbell JAH, Corrigall AV, Kirsch RE. Immunohistologic localization of alpha, mu, and pi class glutathione S-transferases in human tissues. Cancer 1991;67:1608-13.
28. Ranganathan S, Tew KD. Immunohistochemical localization of glutathione S-transferases α, μ, and π in normal tissue and carcinomas from human colon. Carcinogenesis 1991;12:2383-7.
29. McKay JA, Murray GI, Ewen SWB, Melvin WT, Burke MD. Immunohistochemical localization of glutathione s-transferases in sarcomas. J Pathol 1994;174:83-7.
30. Cairns J, Wright C, Cattan AR, Hall AG, Cantwell BJ, Harris AL, et al. Immunohistochemical demonstration of glutathione s-transferases in primary human breast carcinomas. J Pathol 1992;166:19-25.
31. Tanita J, Tsuchida S, Hozawa J, Sato K. Expression of glutathione S-transferase-π in human squamous cell carcinomas of the pharynx and larynx. Loss after radiation therapy. Cancer 1993;72:569-76.
32. Tetsu B, Lacasse B, Bouchard HL, Lagace R, Huot J, Landry J. Prognostic influence of HSP-27 expression in malignant fibrous histiocytoma: a clinicopathological and immunohistochemical study. Cancer Res 1992;52:2325-8.
33. Hurlimann J, Gebhard S, Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 1993;23:239-48.
34. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996;87:2464-9.
35. Moscow JA, Townsend AJ, Cowan KH. Elevation of π class glutathione S-transferase activity in human breast cancer cells by transfection of the GST π gene and its effect on sensitivity to toxins. Mol Pharmacol 1989;36:22-8.
36. Kotoh S, Naito S, Sakamoto N, Goto K, Kumazawa J. Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J Urol 1994;152:1267-70.
37. Harford C, Sarkar B. Studies of induction of metallothionein in JAr (human choriocarcinoma) cells by cis and trans isomers of diamminedichloroplatinum (II) and their hydrolyzed species. Mol Toxicol 1989;2:67-74.
38. Oesterreich S, Schunck H, Benndorf R, Bielka H. Cisplatin induces the small heat shock protein hsp25 and thermotolerance in Ehrlich ascites tumor cells. Biochem Biophys Res Commun 1991;180:243-8.
39. Sato K. Glutathione transferases as markers of preneoplasia and neoplasia. Adv Cancer Res 1989;52:205-55.
40. Chamness GC, Ruiz A, Fulcher L, Clark GM, McGuire WL. Stress responsive protein srp-27 predicts recurrence in node-negative breast cancer. Breast Cancer Res Treat 1988;12:130.
41. Gilbert L, Elwood LJ, Merino M, Masood S, Barnes R, Steinberg SM, et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993;11:49-58.
42. Green JA, Robertson LJ, Clark AH. Glutathione S-transferase expression in benign and malignant ovarian tumors. Br J Cancer 1993;68:235-9.
43. Mulder TP, Verspaget HW, Sier CF, Roelofs HM, Ganesh S, Griffioen G, et al. Glutathione S-transferase π in colorectal tumors is predictive for overall survival. Cancer Res 1995;55:2696-702.
44. Schmid KW, Hittmair A, Tauscher T, Dünser M, Tötsch M, Öfner D, et al. Metallothionein-Expression in Mammakrezinomen - Zusammenhang mit Zytostatikaresistenz, Östrogenrezeptorstatus und Prognose. Verh Dtsch Ges Pathol 1990;74:598.
45. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-31.
46. Tew KD, Bomber AM, Hoffman SJ. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 1988;48:3622-5.
47. Maeda O, Terasawa M, Ishikawa T, Oguchi H, Mizuno K, Kawai M, et al. A newly synthesized bifunctional inhibitor, W-77, enhances adriamycin activity against human ovarian carcinoma cells. Cancer Res 1993;53:2051-6.